

Cancer

A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors

Trial Status
Completed

Trial Runs In
3 Countries

Trial Identifier
NCT02760797 2015-004348-21
BP29427

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is an open-label, multicenter study designed to assess the safety, pharmacokinetics, pharmacodynamics, and therapeutic activity of emactuzumab and RO7009789 administered in combination in participants with locally advanced or metastatic solid tumors that are not amenable to standard treatment. This study will be conducted in two parts: a dose-finding stage (Part I) and an expansion stage (Part II).

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT02760797 2015-004348-21 BP29427
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥ 18 Years

Healthy Volunteers
No